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ROLE OF GLUCOSE TRANSPORTER 1 IN TUMOUR GROWTH
AND RESPONSE TO THERAPY
SJ Brittain-Dissont, KJ Williams, RE Airley, F Sheppard, A Evans,
A Carruthers, IJ Stratford 
United Kingdom, Experimental Oncology, Department of Pharmacy
and Pharmaceutical Sciences, University of Manchester, Manchester
Glut-1 is a facilitative transporter of D-glucose that assists in regulation
of glucose turnover in mammalian cells.  It exists as a plasma membrane-
spanning protein that translocates from vesicular stores to the membrane
in response to hypoxia.  During chronic oxygen and glucose deprivation,
HIF-1 initiates transcriptional de novo synthesis of Glut-1 to counteract
the detrimental conditions. 
We are carrying out a comprehensive study of hypoxia induced Glut-1
expression in a diverse panel of tumour cell lines.  These cells show an
increase in Glut-1 protein expression following 18 hours exposure to
hypoxia (0.001% O2).  Our current experiments are aimed at determining
how long the elevated Glut-1 levels persist for following the return of 
cells to a normoxic environment.  This is to gain an understanding of 
whether Glut-1 expression in tumours will provide a reﬂ  ection of chronic
and/or acute hypoxia.  To carry out these experiments samples of the re-
oxygenated cells are removed at two hourly intervals, centrifuged to form
pellets and formalin ﬁ  xed prior to histological processing and stained 
with antibodies speciﬁ  c for Glut-1. Preliminary evidence in Hepa-1 cells
indicates Glut-1 levels remain high for at least six hours after hypoxia
exposure but return to basal levels after 24 hours.  These experiments
are  being repeated  in other cell  lines. The effect of over expressing
exogenous Glut-1 in tumour cell lines is also under investigation. We have
inserted the cDNA for Glut-1into pEFIRES-P a constitutive mammalian
expression vector developed by Hobbs et al (1998) for stable cell line l
generation and we are currently generating clones. These clonal cell lines
will be used to investigate and validate glucose uptake into tumours and 
its effect on tumour growth. In addition to constitutively over-expressing
Glut-1 we propose to utilize the tetracycline inducible-gene expression
system. This should enable assessment and quantiﬁ  cation of  glucose
uptake relative to the intensity of membrane-bound Glut-1.
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ADENOVIRUS-MEDIATED DELIVERY OF A HYPOXIA-
REGULATED CARBOXYLESTERASE GENE FOR
TUMOUR-DIRECTED ACTIVATION OF IRINOTECAN (CPT-11)
T Matzow 1, PJ Flint 1, RL Cowen 2, KJ Williams 2, IJ Stratford 2,
MP Saunders 1
1 Paterson Institute for Cancer Research, Manchester, United Kingdom,
2 School of Pharmacy and Pharmaceutical Sciences, University of 
Manchester, Manchester, United Kingdom
Irinotecan (CPT-11), a derivative of the topoisomerase I inhibitor camptothecin,
is a chemotherapeutic agent currently used in treatment of colorectal, stomach
and pancreatic cancers. Having poor activity on its own, carboxylesterase (CE)
enzymes convert it into the much more potent compound SN-38. CEs are most
abundant in the liver, where two distinct isotypes, hCE-1 and hCE-2, have been
characterised, the latter being approximately 50-fold more efﬁ  cient at CPT-11
conversion. A third human CE, hiCE, expressed predominantly in the small
intestine, is almost identical to hCE-2. A rabbit liver CE, rCE, has been shown
to convert CPT-11 to SN-38 with 100 to 1000- fold higher efﬁ  ciently than
hCE-1 in vitro, despite sharing >80% sequence homology. The conversion of
CPT-11 to SN-38 by endogenous CE is not very efﬁ  cient, and CE activity is
often further reduced in tumour cells. However, due to dose-limiting toxicity
(including severe diarrhoea), the administered  dose of CPT-11 cannot be
increased to fully compensate for the poor conversion rate.
Hypoxia is common in solid tumours due to inefﬁ   cient and unstructured
angiogenesis. The expression of many proteins, including VEGF, Epo and most
glycolytic enzymes, is regulated by the hypoxia-inducable transcription factor
HIF-1, which speciﬁ  cally  binds to hypoxia responsive enhancer elements
(HREs).
We  have constructed recombinant adenovirus vectors carrying the gene for
either hiCE or rCE, under the control of a HRE derived from the murine PGK-
1 gene, in conjunction with a minimal SV40 promoter. We have demonstrated
enhanced CE-expression combined with increased sensitivity to CPT-11 in
response to hypoxia in cells pre-infected with these viruses in vitro, and are
performing in vivo experiments with the vectors in tumour xenografts.
We hope therapeutic delivery of these vector constructs will allow a signiﬁ  cant
tumour-directed increase in CE expression, thus increasing the potency of
CPT-11 administered at permissive doses.
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INHIBITION OF HYPOXIA-INDUCIBLE CA-IX MODULATES 
ANTICANCER DRUG UPTAKE AND TOXICITY
CA Parker 1, M Jaffar 1, KJ Williams 1, PM Loadman 2, RM Phillips 2,
IJ Stratford 2
1 University of Manchester, Manchester, United Kingdom, 2 University 
of Bradford, Bradford, United Kingdom
The presence of hypoxia within solid tumours is related to increased 
aggressiveness, resistance to therapies and consequently, poor 
prognosis. Carbonic anhydrase-IX  (CA-IX)  is a hypoxia-regulated 
enzyme, overexpressed in many types of human cancer. CA-IX is
involved in pH homeostasis, contributing to extracellular acidiﬁ  cation
and tumourigenesis. Acidiﬁ  cation of the extracellular milieu can impact
upon cellular uptake of chemotherapeutic drugs by favouring weak acids
(e.g. melphalan), but limiting access of weak bases (e.g. doxorubicin).
Thus, the aim of this study was to determine whether alterations of CA-
IX activity affected anticancer drug uptake and toxicity. 
The addition of 50µM CA inhibitor, acetazolamide (AZM), enhanced 
doxorubicin toxicity up to 12 fold, but conversely reduced melphalan
toxicity up to 10 fold in cell lines that highly expressed CA-IX under 
anoxic conditions  (HT29 & MDA435 CA9/18). The changes  in
doxorubicin toxicity were reﬂ  ected in increased passive uptake in anoxic
HT29 and MDA435 CA9/18 cells. AZM limited depletion of GSH by
melphalan in highly inducible cells under anoxic conditions, suggesting
that melphalan uptake was reduced. AZM did not signiﬁ  cantly alter 
toxicity or uptake  in cells with  low CA-IX activity  (HCT116 &
MDA435 EV1). 10-50µM AZM lowered the intracellular pH in HT29
& MDA435 CA9/18 cells under anoxic conditions. The effect of AZM
on doxorubicin uptake and penetration is currently under investigation
in spheroid and multicell layer models, using confocal microscopy and 
HPLC techniques.
CA-IX inhibition under anoxic conditions resulted in acidiﬁ  cation of the
intracellular environment and can enhance or diminish uptake/toxicity
of speciﬁ  c anticancer agents. CA-IX has chemomodulatory properties
and is an attractive target for cancer therapy.
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CORRELATIVE STUDY BETWEEN THE ANGIOGENESIS OF
HCC AND ITS CLINICOPATHOLOGIC RESULTS
Z Gao 1, DX Yu 2, B Wang 2
1 Department of Medical Biology, Weifang Medical University,
Weifang, China, 2 Department of Radiology, Weifang, China
Introduction To study the relationship between the angiogenesis of
hepatocellular carcinoma (HCC), HCC and its clinicopathologic results,
and analyze the associations among microvessel density (MVD), P53 and
vascular endothelial growth factor (VEGF).
Material and Methods The study  group comprised 60 patients who
underwent surgical treatment. Sections were stained w ith p53, VEGF
and CD34immunohistochemically. The tumor size, capsule and edge of
the  lesions were recorded  in surgery. The necrosis,  hyaline-cell areas,
fatty degeneration areas and grades of differentiation were recorded in
pathology. The clinical and histopathological characteristics of the patients
were compared with MVD, p53 and VEGF. 
Results The MVD of HCC in the group without liver cirrhosis was lower
than that in those of liver cirrhosis (P  (P  ( < 0.05). MVD did not correlate
with hepatitis C, necrosis, fatty degeneration, histologic grade or capsule
formation (P  (P  ( > 0.05). VEGF expression was signiﬁ  cantly different between
intrahepatic metastasis and non-metastasis (75% VS 43.18%, P < 0.05),
vascular  invasion and noninvasion  (71.43% VS 41.03%, P < 0.05).
Expression of VEGF was more frequently in HCC with hepatitis B (P (P  ( <
0.05). No signiﬁ  cant correlations were detected between VEGF expression
and fatty degeneration, histologic grade, the size and liver cirrhosis. p53
expression showed a distinctly higher among these groups such as poorly
and moderately differentiation to well differentiation(41.30% VS 7.14%, P
< 0.05), vascular invasion to nonivasion (57.14% VS 20.51%, P < 0.05),
intrahepatic metastasis to nonmetastasis (62.5% VS 22.73%, P < 0.05).
No correlation was found betweeen hepatitis B and C status, the size and
capsule  formation. Signiﬁ  cant correlation was also  found among p53,
VEGF and MVD.
Conclusions There is a statistically signiﬁ  cant correlation between VEGF
and P53 expression (P  (P  ( < 0.05). VEGF associated with P53 inﬂ  uence MVD.
Both P53 and VEGF have a signiﬁ  cantly improved efﬁ  cacy in promoting
tumor angiogenesis and metastasis in HCC.
Posters
S52
British Journal of Cancer (2004) 91(Suppl1), S24–S80 & 2004 Cancer Research UKP94:1
USE OF A NOVEL, HYPOXIA-RESPONSIVE DNA PROMOTER 
IN SALMONELLA TO TARGET GENE THERAPY TO HYPOXIC 
AREAS OF SOLID TUMOURS
R Ryan 1, J Green 1, J Harmey 2, S Kehoe 2, C Lewis 3
1 United Kingdom, Molecular Biology and Biotechnology Dept., 
University of Shefﬁ  eld, Shefﬁ  eld, 2 United Kingdom, Dept. of Surgery,
Royal College of Surgeons in Ireland, Education and Resecrch Centre, 
Beaumont Hospital, Dublin, 3 Ireland, Medical School, University of 
Shefﬁ  eld, Shefﬁ  eld
Multiple areas of  hypoxia and anoxia are features of malignant tumours.
Hypoxic tumour cells are non-proliferating, and therefore relatively refractory 
to radiotherapy and c hemotherapy. This  has prompted t he  development 
of a lternative vectors to target therapeutic genes to these  hypoxic tumour 
areas, including the use of attenuated strains of such bacteria as Salmonella
typhimurium. The expression of therapeutic genes in normoxic tissues is a 
major problem but overcome if an additional level of targeting is included. This
can be achieved by placing a therapeutic gene under the control of a hypoxia-
inducible bacterial transcription factor called Fumarate and Nitrate reduction 
Regulator (FNR). Here, we show that an FNR-regulated promoter (FFpmelR)
activates expression of the reporter gene (lacZ) under hypoxic conditions in  Z) under hypoxic conditions in  Z
an attenuated S. typhimurium strain in vitro. Mutations in the FNR promoter 
improved anoxic induction of the lacZ reporter gene to around 625-fold relative Z
to normoxia and decreased expression under normoxic conditions. This mutant 
FFpmelR::lacZ construct in  Z S. typhimurium was used to infect a human breast 
cancer cell line (T47D). LacZ was expressed when these infected cells Z were
exposed to hypoxia (0.5% oxygen) but not normoxia (20.9% oxygen) for 16h 
in vitro. This S. typhimurium mutant was utilised to inﬁ  ltrate T47D multicellular 
tumour spheroids. The bacteria inﬁ  ltrated the spheroids but lacΖ expression  Ζ
was restricted to the  hypoxic areas of t hese tumour masses. In an in  vivo
experiment,  S. typhimurium  (106) transformed w ith e ither mutant FFpmelR:
:alphastatin (alphastatin is a new anti-angiogenic peptide) or a null construct 
were injected (i.v.) into female BALB/c mice bearing 4T1 mammary tumours,
and tumour volume monitored. The attenuated bacteria were well tolerated and 
tumour growth was halted in those injected with the FFpmelR::alphastatin. We
conclude that FNR-dependent promoters in S. typhimurium can be used to target 
therapeutic gene expression to hypoxic areas of murine tumours.
P95
PROTEOMIC CO-EXPRESSION PATTERNS OF CRITICAL
NORMAL GENES ARE FOUND IN HUMAN CANCER CELL
LINES BUT NOT IN NORMAL CELLS
H. Warenius, l. Seabra, L. Kyritsi, M. Jones, C. Thomas, R. White, 
A. Howarth 
University of Liverpool, Liverpool, United Kingdom
We have carried out proteomic proﬁ  ling of 23 known proteins responsible
for the control of cellular proliferation, differentiation, senescence and
death in 20 human in vitro cancer cell lines covering a wide range
of  histologies and  in primary cultures of normal  keratinocytes and
ﬁ  broblasts. The proteins  include cyclins, cyclin  dependent  kinases,
cyclin dependent kinase inhibitors, proto-oncogenes tumour suppressors
and pro- and anti- apoptotic proteins in addition to normal controls. The
proteomic proﬁ  les obtained are different for each individual cell line,
consistent with the likelihood that each cancer cell may constitute a
unique emergent system. However, certain patterns of close gene product
interaction (with r values greater than 0.5 and p values greater than 0.05)
are discernible. We suggest that these patterns of gene expression may
reﬂ  ect Critical Normal Gene Products whose co-expression is required
to maintain Neostasis in inherently unstable cancer cells. These patterns
of gene product co-expression are not dissimilar to appearances of scale
free systems, where nodes of high interaction can provide the most
vulnerable sites for disrupting the system. The proteomic database of
the cell lines examined here is insufﬁ  ciently large to demonstrate this
formally. Nonetheless an understanding of these patterns of interaction
may lead to different approaches towards identifying novel targets for
new drug development.
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FUNCTIONAL ANALYSIS OF GENE EXPRESSION DIFFERENCES
IN A MODEL OF COLORECTAL CANCER PROGRESSION
E. Foran, F. Lennon, D.T. Croke, A.C. Long
United Kingdom, RCSI, Dublin
Our group has previously identiﬁ  ed a set of genes to be differentially
expressed between the premetastatic cell line SW480 and its metastatic
counterpart, SW620 (1).  The aim of this study was the identiﬁ  cation
of functional differences between SW480 and SW620.  Migration and 
proliferation, two parameters associated with metastasis, were analysed 
using a phagokinetic track assay and an MTS assay respectively   I
Two major areas of cell signalling were investigated –phosphorylation/
dephosphorylation and the PI3-kinase pathway.  Both pathways have
previously been associated with cell migration and proliferation in
epithelial cell lines. A number of interesting observations were made.
First, a role exists for the protein phosphatases 1 and 2A in the control of 
proliferation in SW620.  Also, inhibition of PI3-kinase by wortmannin
in SW480 leads to the development of lamellipodia/pseudopodia in this
cell line, but not in SW620, indicating that PI3-kinase may be involved 
in actin organisation in SW480. These data will contribute to current
knowledge regarding SW480 and SW620 cell lines as a model of 
colorectal cancer progression.
In addition, our group has also determined that the L-plastin gene is
up-regulated in SW620 with respect to SW480.  SW480 cell lines
stably expressing L-plastin were subsequently established  (SW480-
LPL) and analysis of these cell lines revealed a signiﬁ  cantly higher 
rate of proliferation and lower rate of migration than the control cell
line (SW480-pcDNA3.1).  E-cadherin, an important tumour suppressor 
gene was lost from SW480-LPL cells.  A link was elucidated between
L-plastin induction and the down-regulation of E-cadherin, whose loss
of expression is directly associated with the development of metastasis
in several epithelial cancers.  These data could be of importance in
clarifying the mechanisms of colorectal cancer metastasis.
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ANALYSIS OF ABERRANT CPG-ISLAND METHYLATION IN
STAGE III AND IV OVARIAN CANCER
JM Teodoridis, L Braidwood, J Hall, PA Vasey, G Strathdee,
R Brown
United States, University of Glasgow, Glasgow
Ovarian tumours are often diagnosed at late stages III or IV and are
usually treated with surgery followed by platinum-based chemotherapy.
Resistance to chemotherapy is a major cause of treatment failure.
Inactivation of genes involved in cellular responses to DNA damaging
agents, including genes involved in DNA repair, apoptotic signalling
and cell cycle control have been identiﬁ  ed as possible causes of tumour
chemoresistance.. Transcriptional silencing of genes associated with
aberrant methylation of CpG islands represents one possible molecular
cause for chemoresistance and it has been suggested from small
retrospective studies that aberrant DNA methylation can correlate with
disease progression and overall survival in ovarian cancer patients (S. H.
Wei et al., Clinical Cancer Research 8(7) () , p. 2246 (2002)). We set out
to investigate if aberrant DNA methylation of genes involved in cellular
responses to DNA damage can be used to predict tumour response to
chemotherapy or patient survival. To achieve this, DNA from 98 stage
III or IV ovarian tumours taken at presentation was isolated, bisulphite
modiﬁ   ed and analysed by methylation speciﬁ  c-PCR.  CpG  island
methylation was seen in apaf-1 (14.3%), blu (34.7%), brca1 (19.4%),
casp8 (2%), dapk (2%),  k gstπ tπ t (2%), mgmt (10.2%),  t mlh1 (15.3%), p14
(1%), p16 (3.1%), 6 p21 (27.6%), p73 (4.1%), rassf1a (38.8%), but not
in fancf,  f,  f fas or survivin. Methylation of at least one of these genes
was observed in 80.6% of tumours. Thus, CpG island methylation is
a frequent event in late stage ovarian tumours. Statistical analysis of
associations between methylation and clinical outcome is currently
underway.
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DETECTION OF GENETIC ALTERATIONS IN NON-SMALL 
CELL LUNG CANCER (NSCLC) USING INTER-SIMPLE
SEQUENCE REPEAT PCR 
DM Broomhead, TA Bailey, AC Woodman
Cranﬁ  eld Biomedical Centre, Cranﬁ  eld University, Silsoe,
United Kingdom
Lung cancer remains the number one cause of cancer death in the United 
Kingdom. Genetic abnormalities in lung cancer are being increasingly
recognised, although a multi-stage model similar to that described in
other cancers, such as colon, has not yet been deﬁ  ned.
Genomic instability is one mechanism thought to play an important part
in cancer progression, speciﬁ  cally in the early stages, even before the
appearance of any morphological changes. By means of non-radioactive
inter-simple-sequence-repeat PCR (Inter SSR-PCR) we have assessed 
the extent of genomic abnormalities occurring in the progression
of non-small cell lung cancer (NSCLC). Inter-SSR PCR ampliﬁ  es
regions located between repeated sequences and allows the detection of 
chromosomal alterations found in DNA segments.
DNA was extracted from cell lines, of various types and stages of 
NSCLC, and from a “normal” blood sample. It was then ampliﬁ  ed using
the inter-SSR PCR technique described. Band differences between
“normal” and neoplastic samples were identiﬁ  ed by resolution of PCR 
products on an 8% non-denaturating polyacrylamide electrophoresis
gel, followed by silver staining.
By comparison of ﬁ  ngerprints from different sources, a number of 
intensity changes could be visualized. These results demonstrate the
ﬁ  rst step in characterising molecular events, which may be indicative
of carcinoma development, which in turn may allow more precise and 
earlier risk assessment for individual patients, enabling more effective
therapy.
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FINE MAPPING OF GENETIC ALTERATIONS ON
CHROMOSOME 6 IN UVEAL MELANOMA
JM Risk, J Nunn, B Damoto, KE Burrows, S Hagan, AGM Scholes, 
P Hiscott, I Grierson, JK Field 
United Kingdom, The University of Liverpool, Liverpool
Uveal melanoma is the commonest primary intraocular malignant
tumour in adults and approximately 50% of patients develop fatal
metastatic disease which correlates with the observation of monosomy
3 in the tumour.  In this study, allelic imbalance on chromosome 6
was  investigated using 17-37 microsatellite markers  in 103 uveal
melanomas and the results correlated with prognosis.  Allelic imbalance
at one or more polymorphic  loci was detected  in 51/103  (50%)
specimens.  Twenty-six tumours (25%) showed allelic imbalance at
6p markers, with a minimal region of 13.5Mb being detected between
markers D6S344 and D6S1578 (6p25.3-p23).  This was associated
with disomy at chromosome 3, lack of epithelioid cells, and improved
survival.  However, allelic imbalance at 6p markers and monosomy 3
were not mutually exclusive.  Thirty-ﬁ  ve tumours (34%) showed allelic
imbalance at markers on 6q, consisting of partial deletion in 20/35.
However, this was not consistently observed at any one region on 6q and
was not associated with monosomy 3 or survival.  The allelic imbalance
observed at 6p markers has thus been localised to allow further, gene-
speciﬁ  c, studies to be initiated.  The data also suggest that long-term
prognosis in cases with monosomy 3 is improved in the simultaneous
presence of allelic imbalance at 6p markers.
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A BROAD PANEL OF SCREENING ASSAYS FOR MUTATION 
AND METHYLATION ASSESSMENT OF GENES INVOLVED IN 
THE PATHOLOGICAL DEVELOPMENT AND THERAPEUTIC
TREATMENT OF NSCLC: UTILITY FOR EARLY DETECTION
AND PATIENT MONITORING
SL Lilleberg, C Sanders, J Durocher, M Geimer, C Zhi, KB Walters, 
G Hong
United Kingdom, Transgenomic, Omaha
Non-small cell  lung cancers (NSCLC) contain numerous alterations,
including somatic mutations and CpG island hypermethylation in a variety
of genes that contribute to the pathological phenotype.   Some of these
tumor-associated variations have also been detected in the DNA found in
the plasma of NSCLC patients, including DNA with mutations in TP53 and 
KRAS, and hypermethylation in p16INK4a and MGMT.  However, a more
comprehensive study designed to assess both mutation and methylation
status of NCSLC patients at various stages has not been reported.   Here
we describe a combined assay panel for the assessment of genes associated 
with disease pathogenesis and therapeutic treatment of NSCLC.  DNA from
primary tumors and matching patient plasma were screened for mutations in
a variety of genes including PTEN, TP53, TP73, KRAS, NRAS, BRAF, MET,
EGFR, PDGFRA, PDGFRB, and KIT, and alterations of methylation status
in APC, MLH1, p16, p14, MGMT, GSTP1, DAPK, RASSF1A, RUNX3,
RARB2, and FHIT. We chose mutation and methylation scanning technology
and these targets to develop a thorough screening methodology for alterations
known to be associated with NSCLC or that may be involved in resistance
to targeted therapeutics.  Variations were identiﬁ  ed with a denaturing high-
performance  liquid c hromatography  (DHPLC) p latform that uses post-
separation ﬂ  uorescence technology, enabling the detection of variants that
represent < 0.1 – 1.0% of the total analyzed DNA.  Using this approach, we
identiﬁ  ed at least one somatic or epigenetic event in 100% of the NSCLC
patients. In no case was a mutation found in the primary tumor that was not
also present in the plasma. The results emphasis the heterogenous pattern
of genomic alterations and that scanning provides an attractive approach to
comprehensive NSCLC genetic and epigenetic screening. The thoroughness
of approach may have important implications for screening and staging, and 
disease monitoring during and following therapy.
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MICROARRAY ANALYSIS OF OPCML TUMOUR SUPPRESSOR 
FUNCTION IN THE SKOV-3 OVARIAN CANCER CELL LINE
G.J. Rabiasz 1, D. Scott 1, E.P. Miller 1, E.A. Stronach 2, K.J. Taylor 1,
E. Ntougkos 1, H. Gabra 2, J.F. Smyth 1, G.C. Sellar 1
1 Cancer Research UK, Edinburgh, United Kingdom, 2 Imperial
College, London, United Kingdom
We have identiﬁ  ed  OPCML  (OBCAM) from 11q25 as a tumour
suppressor gene frequently inactivated in sporadic epithelial ovarian
cancer  (EOC), the leading cause of death from gynaecological
malignancy. OPCML is a member of the IgLON family o f
immunoglobulin domain-containing  glycosylphosphatidylinosito
l  (GPI)-anchored cell adhesion molecules. GPI-anchored proteins
typically localise to lipid raft microdomains in cell membranes, which
potentially facilitate rapid signalling into the cell. OPCML transfection
into the SKOV-3 ovarian cancer cell lines resulted in phenotypes
consistent with tumour suppressor and cell adhesion molecule function:
growth suppression in vitro and in vivo, and enhanced in vitro cell-cell
aggregation. A somatic mis-sense mutation, P95R, resulted in loss of
OPCML-enhanced cell-cell aggregation function, whereas growth
suppression remained unaffected. Neither the signalling pathway nor
the downstream transcriptional consequences associated with OPCML
function have been described. Therefore, we have set out to determine
the transcriptional changes associated with OPCML function in
SKOV-3 using the CRUK Microarray Consortium 10K cDNA array.
We have compared the expression proﬁ  le of the OPCML-transfected
cell line with the SKOV-3 clonal parent cell line, pcDNA3.1zeo-,
OPCML antisense-, and OPCML P95R-transfected SKOV-3 cell lines.
Expression proﬁ  les have been compared using Gene Spring, and genes
with >2-fold expression differences identiﬁ   ed. In keeping with the
phenotypes being analysed, genes with roles in cell adhesion and growth
suppression have been identiﬁ  ed. Further analysis and validation are in
progress and these will be presented.
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GLOBAL PROFILING OF MOLECULAR MECHANISMS OF
5-FLUOROURACIL RESISTANCE IN HUMAN CANCER CELLS
W Wang 1, J Cassidy 2, E Collie-Duguid3
1 Beatson Institute for Cancer Research, Glasgow, United Kingdom,
2 Beatson Institute for Cancer Research, Glasgow, United Kingdom,
3 University of Aberdeen, Aberdeen, United Kingdom
The expression of over 22,000 human transcripts were analyzed on
Affymetrix HG-U133A oligonucleotide microarrays in 5-pairs of 5-FU
resistant and relevant parental cell lines. 
In unsupervised  hierarchical c lustering, 47 probability  (Welch p<0.05,
Benjamini and Hochberg FDR) and threshold (1.5)  ﬁ  ltered  genes
segregated cells into 5FU sensitive and resistant groups. The expression of 
these genes was not signiﬁ  cantly correlated with the primary tumour type
from which the cell lines were derived (rectal vs breast). A rule that predicted 
5FU sensitivity phenotype with 100% accuracy and high predictive strength
(p ratio <0.08) using leave-one-out cross-validation with the KNN algorithm,
was built from the expression levels of a subset of 12 of these genes.
In supervised analysis, key pathways reported or hypothesized to be important
in the action of 5FU were evaluated.  The expression of 101 transcripts was
altered in at least 4 of the resistant lines and was > 1.5-fold statistically
signiﬁ  cantly altered (p<0.05) between the resistant and sensitive groups.
Protein  levels of some genes were veriﬁ  ed  by Western blot. Expression
of a number of genes involved in 5-FU activation were signiﬁ  cantly down
regulated (TK, 2.9-fold; OPRT, 2.3-fold; UMPK, 3.2-fold; PNP, 3.6-fold) in
resistant cells. In line with previous reports, TS and c-yes over-expression
were detected. Although NF-B p65 mRNA over-expression did not reach
statistical s igniﬁ  cance,  higher NF-B DNA binding and transcriptional
activities were consistently detected in resistant cells. 5FU resistant cell lines
manifested reduced expression of genes governing DNA replication (DNA
polymerase , MCM7), G1-S (cyclin D3, Cdk-2) and S phase (cyclin A)
transition. These ﬁ  ndings were highly consistent with the slower growth rates
of resistant cells and the higher proportion or resistant cells arrested in G1 or 
early S phase. This phenotype may provide resistant cells with time to repair 
genetic damage and escape 5-FU induced apoptosis.
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ARSENIC TRIOXIDE INDUCES CHANGES IN THE GENE
EXPRESSION PROFILE OF ACUTE PROMYELOCYTIC 
LEUKAEMIA AND MULTIPLE MYELOMA CELL LINES
NM Gebril, A Gilkes, K Mills, A Tonks, AK Burnett
University of Wales College of Medicine, Department of Haematology, 
Cardiff, United Kingdom
Arsenic trioxide (AS2O3) has recently been used for the treatment of acute
promyelocytic leukaemia (APL).  The mechanism of action of this drug is
thought to involve the induction of apoptosis and partial differentiation.
AS2O3 also exhibits anti-tumour activity on other malignancies such as
Multiple Myeloma (MM).  The aims of this study were to investigate the
effect of AS2O3 on the gene expression proﬁ  le of APL & MM cells.
APL (NB4 & NB4R2) and MM (SKO-007 & MC/CAR-Z2) cells were
treated  with 2 µM AS2O3 for 24 hours; a dose which  demonstrates  a
signiﬁ  cant effect on cell proliferation and clinically achievable.  cDNA
Microarray analysis (Affymetrix system) was performed to measure and
compare the expression levels of genes in control (untreated) and AS2O3-
treated cells.
Data analysis of NB4, NB4R2, SKO-007 and MC/CAR-Z2 cells
demonstrated that 3575, 4820, 3775 and 4459 genes, respectively were
up- or down-regulated by two-fold in AS2O3-treated cells.  Telomerase
expression was down-regulated in all AS2O3-treated cells, with the most
marked e ffect seen in NB4R2 cells  (3.3 to 0.3 fold).  AS2O3 down-
regulated all Ras members in APL cells.  In contrast, changes in MM cells
were varying, K-Ras was up-regulated and H-Ras was down-regulated.
Moreover, the bcl-2 gene was down-regulated in all AS2O3-treated cells
except in MC/CAR-Z2 MM cells.  The major change in the level of bcl-2
was observed in NB4R2 cells falling from 1.02 to 0.4 fold.  AS2O3 also
up-regulated many genes such as cyclin D1, with the least effect observed
in NB4R2 cells (0.9 to 1.02 fold).  This data might explain the prominent
effect of AS2O3 on refractory/relapsing APL. 
In summary, this data demonstrates that AS2O3 has considerable effects on
a wide range of genes involved in many mechanisms such as proliferation
and differentiation.  In addition, AS2O3 is more effective in the treatment of
refractory APL than ATRA-sensitive APL and MM.
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HIGH LEVEL EXPRESSION OF GN6ST OBSERVED IN A
SUBGROUP OF ACUTE LYMPHOBLASTIC LEUKAEMIA
G Timson 1, S Banavali 2, MI Gutierrez 1, I Magrath 3, KG Bhatia 1,
MH Goyns 1
1 King Faisal Specialist Hospital, Riyadh, Saudi Arabia,
2 Tata Memorial Hospital, Mumbai, India, 3 INCTR, Brussels, Belgium
Microarray analysis is a powerful technology, but its main impact on
routine diagnosis for the near future may be in revealing individual
genes, which are useful diagnostic markers. Recently microarray
analysis  has  identiﬁ  ed a novel subgroup of c hildhood precursor-B
acute lymphoblastic leukaemia (ALL) from a unique gene expression
proﬁ  le of over 30 genes (Yeoh et al., 2002, Cancer Cell, 1, 133-143). We
have evaluated the four most highly expressed genes from this proﬁ  le
to determine whether any of these genes by itself could be useful as a
diagnostic indicator. 
The levels of expression of N-acetylglucosamine-6-O-sulfotransferase
(GN6ST), protein tyrosine phosphatase receptor M (PTPRµ), G protein-
coupled receptor 49 (HG38) and KIAA1099 protein were determined 
by quantitative real time RT-PCR and quantiﬁ  ed by comparison to the
level of expression of GAPDH in the same samples. The peripheral
blood leukocyte or bone marrow samples studied were from a cohort
of 116 pediatric Indian patients diagnosed with precursor-B ALL. In
nine cases, GN6ST was over-expressed at levels 15 to 120 times higher 
than the average of all other samples. PTPRµ was also over-expressed 
in seven of these nine cases and KIAA1099 in eight of them. HG38
exhibited  little correlation with GN6ST expression. The  patients
investigated in this study were ﬁ  rst diagnosed from nine to 18 months
prior to the molecular analysis. Although all of the patients exhibiting
high level GN6ST expression were alive at this time, compared to 72%
of the other patients for whom we had data (60 patients), it is too early
to make deﬁ  nitive judgments about the predictive value of GN6ST over-
expression.
We suggest that high level expression of GN6ST may prove to be a
useful  diagnostic marker  for a subgroup of previously unclassiﬁ  ed 
ALL.
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ON THE GENESIS OF BARRETT’S OESOPHAGUS: A THREE 
DIMENSIONAL STUDY OF THE RELATIONSHIP BETWEEN
OESOPHAGEAL GLAND DUCTS, BARRETT’S OESOPHAGUS 
AND ASSOCIATED SQUAMOUS ISLANDS
RA Coad, PJ Warner, H Barr, NA Shepherd, AC Woodman 
1 Cranﬁ  eld Biomedical Centre, Cranﬁ  eld University, Silsoe, United 
Kingdom, 2 Cranﬁ  eld Postgraduate Medical School in Gloucestershire, 
Gloucester, United Kingdom
Barrett’s oesophagus, an acquired metaplastic condition of the distal
oesophagus, occurs in approximately 10% of patients with gastro-
oesophageal reﬂ   ux disease. The presence of Barrett’s metaplasia
increases a patients risk of developing adenocarcinoma by 30-40%.
This is the cancer with the most rapidly increasing incidence in the
western world and the prognosis for patients is poor. Regression of
Barrett’s oesophagus has been seen in the formation of microscopic
and macroscopic squamous islands following various treatment regimes
The location of the pluripotential stem cells, which give rise to Barrett’s
metaplasia and associated squamous islands, is an area of considerable
contention. There is some evidence which suggests the oesophageal
gland ducts contain this stem cell population, although this is mainly
derived from animal models. 
We have isolated human oesophageal  gland ducts underlying both
Barrett’s oesophagus and squamous islands. By taking serial sections
through these structures we have assessed their interrelationship in the
three dimensions. We have found that oesophageal gland ducts show
deﬁ  nite  morphological continuity with Barrett’s metaplasia. This is
demonstrated  by a gradual transition of t he morphological  features
from the normal cuboidal cells of the duct into the metaplastic cells as
the duct opens onto the mucosal surface. This deﬁ  nite interrelationship
between the structures has not previously been demonstrated in such
a methodical way. We also report the universal association between
squamous  islands and oesophageal  ducts. This  ﬁ  nding conﬁ  rms
previous assumption and is of fundamental importance if we are to
ascertain the origin of Barrett’s oesophagus and develop more targeted
treatment strategies.
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THE 825C>T POLYMORPHISM OF THE G-PROTEIN BETA-3
SUBUNIT GENE (GNB3) AND BREAST CANCER 
P Krippl, U Langsenlehner, H Samonigg
Division of Oncology, Medical University Graz, Graz, Austria
The 825C>T polymorphism in the gene for the G-protein 3 subunit
(GNB3) has been linked to the occurrence of a splice variant of GNB3
and distinct cellular and metabolic features and may be associated with
malignant disease. 500 patients with histologically conﬁ  rmed breast
cancer and 500 female age-matched healthy control subjects were
genotyped for the GNB3 polymorphism to analyze its role for breast
cancer. Prevalences of GNB3 CC, CT and TT genotypes were similar 
among patients  (49.7, 39.8, 10.5%) and controls  (50.1, 42.4, 7.5%,
P=0.25). The GNB3 genotype was furthermore not linked to tumor size,
histological grading, estrogen or progesterone receptor status and age
at diagnosis. In an exploratory analysis, carriage of a 825-T allele was
associated with a longer metastasis-free period in patients with primary
low-grade breast cancer, but not in those with primary high-grade breast
cancer (Cox regression, P=0.025). We conclude that the GNB3 825C>T
polymorphism does not appear to be associated with breast cancer risk,
but may inﬂ  uence development of metastasis in low-grade tumors.
P107
CHARACTERISATION OF NOVEL, FRAGMENT-DERIVED
INHIBITORS OF CYCLIN DEPENDENT KINASES 1 AND 2 AS 
POTENTIAL DRUG-LIKE MOLECULES
JE Curry, R Anthony, V Berdini, DJ Davis, EJ Lewis, L Magor,
M O’Reilly, M S Squires, A Woodhead, P G Wyatt 
Astex Technology, Cambridge, United Kingdom
Cyclin Dependent Kinases (CDKs) play key roles in regulating the
eukaryotic cell cycle.  Two of particular interest are CDKs1 and 2,
which act at the G2/M DNA damage and G1/S cell cycle checkpoints
respectively.  Deregulation of the cell cycle is associated with a number
of  human cancers. As such t hese  kinases are attractive oncology
therapeutic targets for small molecule inhibitors in order to modulate
these key pathways. 
We have used high throughput X-ray crystallography to identify a range
of potent, novel fragment based hits against CDK1 and 2.  Further
rounds of chemical rational design, guided by crystal structures and
potency against relevant CDKs, rapidly developed these initial hits into
tractable lead molecules with sub-nanomolar potencies against CDKs
1 and 2.  
These lead molecules were characterised in a range of cell-based assays
that demonstrated their effectiveness as inhibitors of cell proliferation
resulting from a speciﬁ  c cell cycle arrest.  The mechanism of action
of this inhibition was conﬁ  rmed by monitoring the phosphorylation of
downstream substrates. 
Furthermore the compounds were shown to exhibit negligible toxicity
towards non-proliferating ﬁ  broblast cells, and were equipotent in cells
overexpressing P-glycoprotein or those lacking p53.  Members of active
series had good pharmacokinetics.
In conclusion the characterisation of these inhibitors indicates they have
drug-like properties, suitable for further development.
P107:1
ENGINEERING AUTOLOGOUS MACROPHAGES TO RECOGNISE
AND ERADICATE ESTABLISHED TUMOURS
A Biglari, DG Gilham, LB Woolford, LJ Fairbairn
United Kingdom, Paterson Institute for Cancer Research, Manchester
Macrophages extensively inﬁ   ltrate tumours and can mediate anti-
tumour immunity through antigen presentation and cytokine secretion.
Importantly, these cells also initiate antibody-dependent cellular 
cytotoxicity (ADCC) through the activity of Fc-γ-receptors. We aim to γ-receptors. We aim to  γ
exploit these activities through the speciﬁ  c targeting of macrophages
to tumour by the expression of chimeric Fc-γ-receptors. The chimeric γ-receptors. The chimeric  γ
receptors are targeted by single chain Fvs (scFvs), which speciﬁ  cally
bind either carcinoembryonic antigen (CEA) or 5T4 oncofetal antigen
fused to the Fc−γ receptor chain. Our present studies have used two γ
differing approaches in order to investigate the anti-tumour activity
of modiﬁ  ed  macrophages in murine model systems. In the ﬁ  rst
approach, we are assessing the potential of retrovirally modiﬁ  ed murine
hematopoietic stem cells to generate macrophage cells expressing
the recombinant Fc-γ-receptors in order to target antigen-speciﬁ  c γ-receptors  in  order  to  target  antigen-speciﬁ  c  γ
tumour cells. In the second approach, we are evaluating the efﬁ  cacy of 
adenovirally modiﬁ  ed primary human monocytes expressing the Fc-γ- γ- γ
receptors to recognise and kill tumour cells. We have demonstrated that
both human and mouse primary monocytes expressing the recombinant
Fc-γ-receptors can target and kill tumour cells γ-receptors  can  target  and  kill  tumour  cells  γ in vitro and, on co-
administration with tumour to mice, lead to reduced tumour growth in
vivo and a survival advantage in these animals. These data suggest that
targeted macrophages may be a useful means of delivering a speciﬁ  c
anti-tumour effect.
P107:2
ABERRANT PROTEIN EXPRESSION OF NEK2 KINASE IN
HUMAN TUMOURS
D.G. Hayward 1, R.B. Clarke 2, A.J. Faragher 3, M.R. Pillai 4,
I.M. Hagan 2, A.M. Fry 1
1 Japan, University of Leicester, Leicester, 2 United Kingdom, Paterson
Institute for Cancer Research, Manchester, 3 United Kingdom, MRC 
Toxicology Unit, Leicester, 4 United Kingdom, Institute of Animal 
Health, Pirbright
Nek2  is a ubiquitously expressed serine/threonine  kinase  involved  in
regulation of the cell cycle. It localises to the centrosome throughout the
cell cycle and functional studies in human, Xenopus, Drosophila and fungal
systems implicate it in regulating both centrosome structure and mitotic
progression (1). Currently there is considerable interest in determining
whether centrosomal protein kinases that promote mitotic progression, such
as Cdk1, Aurora A, Plk1 and Nek2, are tumorogenic when upregulated and
hence are viable chemotherapeutic targets (2,3).
We report the elevation of Nek2 protein levels both in several cancer derived
cell lines and in primary human breast tumours. We demonstrate that Nek2
exhibits increased expression at the protein level in speciﬁ  c prostate, ovarian
and leukemic cell lines. Additionally, examination of breast tumours from 20
patients showed protein upregulation in 75% of cases, the ﬁ  rst determination
of aberrant
Nek2 expression in solid tumours. Finally we show that overexpressing
wild type Nek2 in a normal cultured breast epithelial cell background
leads to centrosome and nuclear abnormalities indictative of the abnormal
segregation of chromosomes
Nek2 is now not only implicated in mitotic defects in cell culture models but
also detectable in human tumours from the earliest stages of formation. This
presents the possibility of Nek2 acting not only as a prognostic marker but as
a viable target for therapeutic intervention.
References
(1) Fry AM. (2002). Oncogene, 21, 6184-6194.
(2) Zhou H, Kuang J, Zhong L, Wen-lin K, Gray JW, Sahin A and Brinkley
R. (1998). Nat. Genet., 20, 189-193.
(3) Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL and
Ferris DK. (1997). Biochem. Biophys. Res. Comm.234, 397-
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CO-ORDINATED REGULATION OF THE TUMOUR SUPPRESSOR 
GENE P16 BY B-CATENIN-LEF-1 AND ETS TRANSCRIPTION 
FACTORS.
C Murphy, M El-Tanani, FC Campbell
United Kingdom, Surgery, Cancer Centre, The Queen’s University of 
Belfast, Belfast
Background: Dysregulation of p16 is a crucial step in malignancy.
p16 acts as a tumour suppressor and encodes a cyclin dependent kinase
inhibitor which disrupts progression of the cell cycle. The p16 promoter 
sequence contains 2 DNA binding sites for Ets transcription factors and 
4  for Lef-1. -catenin-Lef-1  is central to colorectal tumourigenesis
and Ets transcription factors play a role in initiation of these tumours.
Together these molecules may play a role in dysfunction of p16 leading
to neoplastic transformation in the colon.
Aims: This study tests the hypothesis that Ets transcription factors co-
operate with -catenin-Lef-1 in the regulation of p16 transcription.
Methods:  Rama37 cells were transiently co-transfected with a p16
promoter  luciferase reporter construct and a combination of stable
mutant -catenin, Lef-1, Ets-1 and Ets-2 cDNA. p16  promoter 
transactivation was assessed using a luciferase assay.
Results: Over-expression of the stable mutant form of -catenin or 
Lef-1 induced p16 promoter reporter construct by a 4-5-fold increase
compared to empty vector (control). Co-transfection of expression
vectors for Ets-1 or Ets-2 with -catenin and Lef-1 activated the p16
promoter reporter gene by a 26-fold and 45-fold increase, respectively.
PEA3 reduced p16 promoter activity of Ets 1 and -catenin-Lef-1 to
4 fold. 
Conclusions: Our data show that Ets-1 and Ets-2 transcription factors
synergize with -catenin-Lef-1 to upregulate p16 transcription whilst
PEA3 suppresses p16 promoter activity and may act as a negative
competitor of Ets1 and Ets2. These events may contribute to colonic
tumourigenesis.
P107:4
THE INTERACTION OF TCF-4 ON OSTEOPONTIN GENE
EXPRESSION IN RELATION TO BREAST CANCER
METASTASIS.
C Mason, FC Campbell, M El-Tanani
United Kingdom, Surgery, Cancer Centre, The Queen’s University of 
Belfast, Belfast
Introduction: Metastasis of common solid tumours is a complex
process of both genetic and phenotypic change resulting in tumour cell
dissemination.  The adhesive glycoprotein osteopontin (OPN) has been
implicated not only in disease progression and metastasis in rodents, but
also as a prognostic factor of metastasis and patient demise in human
cancer.  Osteopontin expression is regulated by the Wnt/Tcf signalling
pathway.  It has been shown that transient transfection of Tcf-4 cDNA
reduces OPN levels in rat mammary carcinoma cells, potentially reducing
the metastatic ability of these cells.  This study will attempt to elucidate
the role of Tcf-4 signal transduction in osteopontin regulated metastasis.  
Aim:  To study the mechanism of action of Tcf-4 and other unknown
genes upon osteopontin transcription and metastases.
Materials and Methods:The effects of Tcf-4 and OPN were investigated
in vitro.  Osteopontin cDNA was cloned into a tetracycline inducible
expression system (T-Rex) (Invitrogen), a constitutive pBK-CMV
expression vector (Stratagene), each construct was stably transfected into
Rama 37 cells. OPN levels were assessed by western blotting.  Invasion
and migration assays were carried out in matrigel models.  
Results: The expression of OPN in TRex (– tetracycline) was similar to
the control non transfected Rama 37 cells but with 1.2 µg/ml tetracycline
was enhanced 6 fold. The constitutive active system pBK-CMV-Rama
37 enhanced 16 fold increased above the non-transfected Rama 37 cells.
Over-expression of OPN in TRex system or constitutive expression cells
shown to induced invasion and migration ability of Rama 37 cells in
vitro.  
Conclusions:  The metastatic ability of osteopontin has been conﬁ  rmed
in vitro.  The effect of Tcf-4 on OPN expression, invasion and migration
will be determined.
P107:5
REGULATION AND EXPRESSION OF ARGININOSUCCINATE 
SYNTHETASE IN HUMAN OVARIAN CANCER
PW Szlosarek 1, MJ Grimshaw 2, GD Wilbanks 3, F Burke 1,
JL Wilson 1, FR Balkwill 1
1 United Kingdom, Barts and The London, London, 2 United Kingdom, 
Guy’s Hospital, London, 3 United Kingdom, University of South
Florida, Tampa
Tumour necrosis factor-α (TNF-α) is implicated in the development
of human ovarian cancer, with increased expression linked to the
upregulation of proinﬂ  ammatory pathways, including c ytokines,
cell adhesion molecules and enzymes. We have recently identiﬁ  ed 
argininosuccinate synthetase (ASS) as a novel proinﬂ  ammatory enzyme
regulated by TNF-α in a subset of ovarian carcinoma cell lines. Here,
we extended this observation to a panel of primary ovarian tumour cells,
conﬁ  rming induction by 24hrs following incubation with 20ng/ml of 
TNF-α. Autocrine TNF-α was required for maximal ASS induction. In
contrast, there was no evidence for ASS induction by TNF-α in normal
ovarian surface epithelium (OSE). A cancer proﬁ  ling array revealed 
increased expression of both TNF-α and ASS mRNA in ovarian tumours
compared with corresponding normal tissue. Immunohistochemistry
conﬁ   rmed presence of ASS protein in ovarian cancers with absent
staining in normal OSE. We also determined the effect of TNF-α on
ASS enzymic activity and showed that TNF-α acts as a survival factor 
for ovarian cancer cells under arginine-free conditions. Finally, we
assessed ASS expression in two murine cancer models and explored the
effect of targeting ASS with TNF-α neutralising antibodies on tumour 
development. In summary, we show that ASS, with its dual role in nitric
oxide synthesis and the arginine-citrulline cycle, is upregulated in
human ovarian cancer. Moreover, ASS expression could be modulated 
using speciﬁ  c TNF-α neutralising antibodies and the combination with
arginine depletion may provide a novel approach to the treatment of 
ovarian cancer.
P107:6
EXPRESSION PROFILING OF CHROMATIN REMODELLING
GENES IN BLADDER AND RENAL CANCERS
A Veerakumarasivam, H Ozdag, A Terschendorff, S Batley,
I Mills, D Neal, T Kouzarides, C Caldas, J Kelly 
United Kingdom, University of Cambridge, Cambridge
Post translational modiﬁ   cation of histones that are involved in
chromosome remodelling appears to have a key role in the regulation
of gene expression. Transcription becomes active when histones are
acetylated by histone acetyltransferases (HAT), silenced when histones
are deacytelated by histone deactylases and silenced or activated when
methylated by histone methyltransferases (HMT). However, deacetylase
activity can contribute to gene activation as well, as shown previously in
Drosophila and Saccharomyces cerevisiae. Acetylation of core histones
has also been correlated with cellular processes, including chromatin
assembly, DNA repair, and recombination. The combination of these
modiﬁ  cations gives rise to what is known as the “histone code” which
could result in epigenetic changes in tumorigenic pathways. Expression
of Histone Deacytelases (HDAC1, HDAC2, HDAC4, HDAC5, HDAC7, (HDAC1, HDAC2, HDAC4, HDAC5, HDAC7,  (
hSIRT1), Histone Methyltyransferases  (SUV39H1, SUV39H2) and
Histone Acetyltransferases (P300, CBP , PCAF (P300, CBP, PCAF ( ) was investigated using F) was investigated using  F
real-time QRT-PCR on 127 bladder tumours, 20 normal bladder, 80 renal
tumours, 12 normal renals and 7 bladder cell lines (UMUC-3, EJ28,
HT1197, HT1376, RT112, T24 and 253J). This study on chromatin
remodelling genes will give important insights into the tumorigenesis
and the molecular proﬁ  ling of bladder and renal tumours.
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NOVEL ANTICANCER PROPERTIES OF POMEGRANATE
EXTRACTS; SUPPRESSION OF PROLIFERATION, INVASION AND
XENOGRAFT GROWTH OF HUMAN PROSTATE CANCER CELLS
L.M. Gommersall 1, M. Albrecht 2, W.G. Jiang 3, J. Kumi-Diaka 5,
E.P. Lansky 4, M.J. Campbell 1
1 Institute of Biomedical Research, University of Birmingham,
Birmingham, United Kingdom, 2 Institute of Anatomy, Philipps
University, Marburg, Germany, 3 Department of Surgery, University 
of Wales College of Medicine, Cardiff, United Kingdom, 4 Rimonest 
Ltd., Nesher, Israel, 5 Divisionof Science, Florida Atlantic University,
Daivie, United States
We have investigated the effects of several Pomegranate fruit (Punica granatum) (Punica granatum)  (
extracts on the proliferation of normal,  benign  hypertrophic, and malignant
prostate cells. Pomegranate juice contains anthocyanins and phenolic acids with
demonstrated antioxidant and anticancer properties.  Cell proliferation and cell
cycle analyses combined with staining of apoptotic cells were used to determine
the effects of cold-pressed seed oil (Oil), fermented juice polyphenol fractions (W) W)  W
and aqueous pericarp extract (P (P ( ) on prostate cells. To evaluate changes in the gene
expression proﬁ  le following extract stimulation, we performed real-time RT-PCR 
studies. In vitro cell invasion assays and xenograft experiments were performed to
test the inﬂ  uence of pomegranate extracts on cell invasion and metastasis.
  Oil, W and  W P all acutely inhibited  P in vitro proliferation of LNCaP, PC-3 and 
DU 145 cancer cell lines. The dose of P required to inhibit cell proliferation of 
the androgen independent prostate cancer cell line DU 145 by 50% (ED50) was
30 µg/ml, whereas normal prostate epithelial cells (hPrEC) were signiﬁ  cantly
less affected (ED50 250 µg/ml). These effects were mediated by changes in cell
cycle distribution and induction of apoptosis. For example, DU 145 cells showed 
signiﬁ  cant increase from 11% to 22% in G2/M cells (p (p ( <0.05) by treatment with
Oil (35  l µg/ml), and induction of apoptosis. These cellular effects coincided with
rapid changes in mRNA levels of gene targets. Thus, 4 hr treatment of DU 145
cells with Oil (35  l µg/ml) resulted in signiﬁ  cant 2.3 fold upregulation of the CDKI
p21(waf1/cip1) (p (p ( <0.01) and 0.63 fold downregulation of c-myc (p (p ( <0.05).  In parallel,
all agents potently suppressed PC-3 invasion through Matrigel, and furthermore
P and supercritical CO P 2 extracted pomegranate seed oil (S) S) S demonstrated potent
inhibition of PC-3 xenograft growth in athymic mice.  Overall this study
demonstrates signiﬁ   cant antitumor activity of pomegranate-derived materials
against human prostate cancer.
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IDENTIFICATION OF STANDARD REFERENCE COMPOUNDS
FOR USE IN A PANEL OF HUMAN XENOGRAFTS IN NUDE
MICE
PT Anstruther 1, S Lynagh 1, S Crawford 1, J McPhail 1, J Gillard 1,
R Hull 2, JA McKay 1
1 Quintiles Limited, Edinburgh, United Kingdom, 2 James Black 
Foundation, London, United Kingdom
The nude mouse xenograft model is a well-established technique used to
study the anti-tumour activity of potential novel therapeutics. However,
available data detailing speciﬁ  c interactions between reference compounds
and tumour cell lines is limited. Hence, we have tested a number of utilised
chemotherapeutics against a range of human tumour xenografts in the
nude mouse.
Cell suspensions were grown in vitro, and implanted subcutaneously into
the ﬂ  ank of athymic nude mice. Once palpable tumours had established,
mice were treated with various anti-cancer drugs, and tumour volumes
measured regularly.
Paclitaxel  (20 mg/kg  i.v.) s igniﬁ  cantly reduced  growth o f t he uterine
xenograft MES-SA (P (P ( <0.001), and t he colorectal tumours HT-29,
HCT116 and LoVo (P (P ( <0.01), however no signiﬁ  cant reduction in growth
rate was observed  in the colorectal xenograft DLD-1. Gemcitabine
(Gemzar®, 100 mg/kg i.p.) signiﬁ  cantly reduced the tumour volume of
BxPC-3 (pancreatic) and LoVo xenografts (P (P ( <0.001). The growth of LoVo
tumours was also reduced following treatment with 5-ﬂ  uorouracil (5-FU,
50 mg/kg i.v.; P<0.05). However, no signiﬁ  cant effect on tumour growth
was observed in DLD-1 or HCT116 xenografts when treated with 5-FU
(25 mg/kg  i.v.). Mitomycin C  (2 mg/kg  i.p.) s igniﬁ  cantly reduced t he
mean tumour volume of the NCI-H460 lung xenograft (P (P ( <0.001), but was
without inﬂ  uence on HT-29 or MES-SA tumours. Cisplatin (4 mg/kg i.v.)
signiﬁ  cantly reduced mean tumour volume of the NCI-H460 xenografts
(P (P ( <0.01), while no signiﬁ  cant reduction in growth rate was observed in
MES-SA tumours.
In conclusion, variable efﬁ   cacy of chemotherapeutics was observed
between human tumour xenografts. This data is pertinent for the selection
of appropriate reference compounds for evaluation of novel anti-cancer
compounds in vivo.
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FEASIBILITY OF UTILISING THE HOLLOW FIBRE (HF) ASSAY
TO INVESTIGATE THERAPEUTIC RESPONSE IN THE EWING’S 
SARCOMA FAMILY OF TUMOURS (ESFT)
EM Bridges 1, MC Bibby 2, S Dalal 1, SA Burchill 1
1 Cancer Research UK, St James’s University Hospital, Leeds, United 
Kingdom, 2TCCRC, Bradford University, Bradford, United Kingdom
The NCI HF anti-cancer drug screen is a rapid in vivo assay to evaluate
novel chemotherapeutic drugs prior to full xenograft screening. The
feasibility of using HF to evaluate the effects of chemotherapeutic drugs
and novel treatment strategies in ESFT cells has been assessed.  Viable
cell number and growth kinetics of six ESFT cell lines in HF has been
studied by the trypan blue exclusion assay. The histology of the ESFT
cells in parafﬁ  n-embedded HF has been examined by staining with H&E
and microscopy. Assays for proliferation (immunohistochemistry for 
Ki67) and apoptosis (TUNEL) have been optimised for use in the HF.
The effects of doxorubicin (0.1µg/ml) on cell morphology, proliferation
and apoptotic index of ESFT cells seeded in HF have been evaluated.
All six ESFT cell lines have been successfully seeded into HF. Viable
cell number increased exponentially with time (0-96h). A673 cells grew
as spheroids with a highly proliferative outer rim (100µM) and an inner 
necrotic centre. SK-N-MC cells formed cell clumps, and the remaining
cell lines studied grew as a homogenous mass within the HF.  Two cell
lines, RD-ES and SK-ES1, produced rosettes consistent with ESFT
histology. Following treatment with doxorubicin viable cell number 
within the HF decreased in a time dependent manner (24-96h). The
A673 cells in HF were more resistant to the induction of apoptosis by
doxorubicin than the other cell lines studied, consistent with effects on
substrate adherent cultures. Doxorubicin increased the apoptotic index
of cells in HF; this was associated with a decrease in proliferation. The
organised morphology of A673 spheroids was lost in a time dependent
manner after exposure to doxorubicin. In conclusion the HF assay
may provide a reproducible high through-put screen to assess novel
therapeutic strategies in ESFT. Using the HF it is possible to obtain pure
populations of ESFT cells to evaluate tumour markers and biologically
signiﬁ  cant end-points in a pharmacologically relevant in vivo model.
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A QUANTITATIVE METHOD FOR MEASURING
THREE-DIMENSIONAL INVASION IN VITRO USING 
ORGANOTYPIC CULTURES
M Nystrom 1, M Stone 2, GJ Thomas 3, I Mackenzie 4,
IR Hart 1, JF Marshall 1
1 Cancer Research UK Clinical Centre, London, United Kingdom,
2 Richard Dimbleby Department of Cancer Research, London,
United Kingdom, 3 Eastman Dental Institute, London, United Kingdom,
4 Bart’s and the London Medical and Dental School, London,
United Kingdom
Invasion by carcinoma cells requires an active interplay with cells of the
host stroma, particularly the ﬁ  broblasts.  Thus assays that measure tumour
invasion in vitro in the presence of ﬁ  brobasts better replicate the in vivo
situation.  In order to study invasion in vitro we have used an organotypic
skin model, a technique whereby a stratiﬁ  ed epithelium is created by plating
carcinoma cells onto a collagen gel embedded with ﬁ  broblasts. Although
invasion through t he  gel  looks similar to the  in vivo situation a major
disadvantage is that this method is not quantitative and thus has limited use
as a tool for assessing and comparing the efﬁ  cacy of anti-invasive therapies.
To address this problem we have devised a computer-based method of
quantitating invasion. Sections (4um) cut from parafﬁ  n embedded gels were
stained with the pan-cytokeratin antibody AE1/AE3 and were photographed.
Using image analysis software (Optilab;Graftek, France) a calibrated binary
image was generated which then was converted into a ‘convex’ image that
encompassed all of the carcinoma tissue. From this single image the mean
chord Y (mean vertical depth of invasion) was calculated.  Image analysis
of serial sections showed that carcinoma invasion varied only 5-10% across
180um of the centre of gels conﬁ  rming that the assay was robust.  Using this
method we have shown that human foreskin ﬁ  broblasts promote ﬁ  ve-fold
more invasion of CA1 cells (an oral squamous cell carcinoma line) than do
NIH 3T3 murine ﬁ  broblasts conﬁ  rming that the source of ﬁ  broblasts has an
important impact on tumour cell behaviour. Various inhibitors of invasion
have been screened and it was shown in several replicate experiments that the
cyclo-oxygenase inhibitor, NS398, inhibits invasion of CA1 cells by 50% .
We propose that this method for quantitating invasion in the organotypic skin
model is a valuable, reliable and accurate way of screening for anti-invasive
therapies.
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USE OF A PRIMARY LYMPHOMA CULTURE SYSTEM TO 
INVESTIGATE THE IN VITRO ACTIVITY OF BORTEZOMIB
L Maharaj 1, SJ Strauss 1, J Stec 2, SP Joel 1, TA Lister 1
1 Department of Medical Oncology, St. Bartholomew’s Hospital, West 
Smithﬁ  eld, London, United Kingdom, 2 Millennium Pharmaceuticals, 
Boston, United States
A primary lymphoma culture system based on the CD40-CD40L interaction
has previously been reported (Johnson et al, Blood. 1993 5;82(6):1848).
This has been modiﬁ  ed and validated prior to evaluating the activity of the
proteasome inhibitor bortezomib in primary follicular lymphoma (FL) and 
mantle cell lymphoma (MCL) cultures.
Single B-cell suspensions were isolated  from  lymph nodes, ascites or 
peripheral blood from 10 patients with histologically conﬁ  rmed FL or MCL.
After disaggregation and/or density gradient separation, cells were plated 
at a density of 5x105 cells/well into 96-well plates containing CHO cells
transfected with the CDw32 Fc receptor to express the CD40 ligand, which,
when irradiated to prevent further proliferation, provide a stromal layer 
supporting B-cell proliferation. Malignant or normal B-cells were cultured 
in IMDM medium supplemented with 10% human serum and 2ng/ml IL-4,
and could be maintained for up to 8 days whilst retaining close phenotypic
resemblance to the original sample, conﬁ  rmed  by  ﬂ  ow  cytometric
quantitation of cell surface markers. After 24hrs drug was added at varying
concentrations in triplicate and cell number and viability were assessed after 
a further 48hrs using the trypan blue exclusion assay. EC50 values for %
viability were derived for each sample using Graphpad Prism. 
MCL cells were typically more sensitive to bortezomib than FL cells
(median EC50 156ηM range (123-727ηM), vs 925ηM (206-1600ηM)
respectively, Mann-Whitney U-test  P=0.09, n=5 for each). In contrast,
there was no difference in sensitivity to doxorubicin between MCL and 
FL cells (median EC50 4.1µM range (2.0-6.3µM) vs 2.3µM (1.5-5.5µM)),
these patients having previously failed an anthracycline-containing regimen.
Furthermore, three of the MCL samples were from patients subsequently
treated w ith  bortezomib.  In vitro sensitivity to the  drug correlated w ith
clinical response, suggesting the possible use of this system as an in vitro
predictor of response to chemotherapy.
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A DOSE-ESCALATION-STUDY EVALUATING THE TOXICITY 
AND THERAPEUTIC EFFICACY OF 131I LABELLED CHIMERIC 
ANTIBODY CHT-25 IN PATIENTS WITH IL-2 EXPRESSING
LYMPHOMAS. PRELIMINARY RESULTS
JA Violet, R Francis, JR Buscombe, J Croasdale, S Parker,
P Amlot, AJ Green, A Hilson, RH Begent 
United Kingdom, Royal Free Campus, University College London, 
London
In this phase I/II study 131I labelled CHT-25 (a chimeric human/ mouse IgG1
whole antibody) directed against the IL2 receptor has been administered
to patients with IL2 expressing NHL and Hodgkin’s disease. Cohorts of
three patients with refractory, relapsed lymphomas were treated with equal
doses of CHT-25 labelled with 131I. Activities were administered from 370
MBq/m2 to 2990 MBq/m2. Patients receiving activities greater than 1440
MBq/m2 required stem cell harvesting. F-18 FDG PET and CT were used
to assess response with SPECT and blood activity counting to determine
biodistribution. Toxicity was assessed according to NCI toxicity criteria,
response by WHO criteria
7 patients have been recruited including 4 with Hodgkin’s and 3 with non-
Hodgkin’s lymphoma. Six of the seven patients have previously undergone
high dose chemotherapy with peripheral stem cell rescue. Patients received
activities ranging from 488 MBq to 4762 MBq per administration. Four
patients had multiple therapies with the maximal administered total activity
being 10.7GBq. 2 patients, receiving t he  lowest activity,  discontinued
treatment after the ﬁ  rst cycle due to progression. One patient has achieved
complete remission based upon F-18 FDG PET imaging and CT which
is sustained for greater than 12 months. A partial response has been seen
in another 2. A further patient achieved stable disease following a single
treatment. There has been a single toxic death. Blood activity counts showed
persistent circulating antibody with a T1/2 of more than 50 hours; this is also
reﬂ  ected in the scan appearances up to 96 hours post injection. 
In conclusion, this preliminary analysis of  131I  labelled CHT-25 has
demonstrated an encouraging response which appears related to administered
activity in this heavily pre-treated group of IL2 expressing Hodgkin’s disease
and NHL. This has been achieved with manageable toxicity and justiﬁ  es
further study.
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IN VITRO PREDICTION OF CYTOCHROME P450 MEDIATED 
INTERACTIONS BETWEEN CHEMOTHERAPEUTIC DRUGS 
AND COMMON CO-MEDICATIONS
SJ Brown 1, CJ Ward 1, J Yu 1, M Paine 1, CR Wolf 1, EM Rankin 2
1 United Kingdom, Cancer Research UK Molecular Pharmacology 
Unit, Biomedical Research Centre, Ninewells Hospital and Medical
School, Dundee, 2 United Kingdom, Division of Cancer Medicine,
Ninewells Hospital and Medical School, Dundee
Cancer chemotherapy is an area of medicine where signiﬁ  cant drug
interactions are likely to occur.  Most chemotherapeutic agents have
a narrow therapeutic index and are used in combination with many
other drugs that relieve disease symptoms and side effects of treatment.
Adverse drug effects caused by co-medications may go unrecognised 
as they may be assumed to be side effects of t he chemotherapy.
Conversely, interactions between co-medications and anti-cancer drugs
may produce side effects of such severity that subsequent doses of the
anti-cancer drug are reduced (potentially compromising therapeutic
efﬁ  cacy) w hereas  in  fact the co-medication should  be altered.
Interactions between commonly used medications and cytotoxic drugs
may arise by inhibition of cytochrome P450 (CYP) enzymes.  These
interactions could lead to alteration of the circulating concentration
of cytotoxic drugs, causing increased toxicity or reduced efﬁ  cacy.  In
this study we have evaluated a range of over 40 common medications
(identiﬁ  ed from an audit of over 100 newly diagnosed cancer patients)
for their ability to inhibit three medically important CYP isoforms – 
CYP2C8, CYP2D6 and CYP3A4, which are involved in the metabolism
of many anti-cancer drugs as well as anti-emetics and analgesics.  These
tests identiﬁ  ed a number of commonly used drugs which inhibit CYP
isoforms in vitro at clinically relevant concentrations e.g. omeprazole
(CYP2C8), ﬂ  uoxetine (CYP2D6) and domperidone (CYP3A4).  Drugs
identiﬁ  ed as potent inhibitors of CYP450s should  be considered as
potentially being involved in drug-drug interactions and further study
in vivo to conﬁ  rm this would allow development of strategies to avoid 
unwanted interactions with chemotherapy.
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IN-VIVO PHENOTYPING FOR CYTOCHROME P450 CYP3A4 IN 
CANCER PATIENTS
SJ Brown 1, CJ Ward 1, D Forbes 1, CR Wolf 1, EM Rankin 2
1 United Kingdom, Cancer Research UK Molecular Pharmacology
Unit, Biomedical Research Centre, Ninewells Hospital and Medical 
School, Dundee, 2 United Kingdom, Division of Cancer Medicine, 
Ninewells Hospital and Medical School, Dundee
The drug-metabolising enzyme cytochrome P450 (CYP) 3A4
shows marked variability, which may explain some of the variation
in pharmacokinetics of cytotoxic drugs which are metabolised by
CYP3A4.  In those where the dose of anti-cancer drug (based on Body
Surface Area) is too high, excessive toxicity will lead to dose reduction
in subsequent treatment cycles.  Approximately 30% of patients are
thought to be undertreated, which would impact on anti tumour effects
of therapy.  A reliable means of predicting in which patients the dose
needs escalation is required.  Assessment of CYP3A4 activity may
give a more accurate way of determining the dose of these drugs for an
individual patient.  To determine an individual’s CYP3A4 activity we
have used midazolam in an in-vivo phenotyping test.  We have looked at
30 subjects to see if this method is safe and applicable in cancer patients,
who may have liver disfunction and may be taking medications which
can induce or inhibit CYP3A4 activity.  Cancer patients were given 1mg
of intravenous midazolam, and the pharmacokinetic parameters were
evaluated by serial blood sampling over 6 hours.  5-fold inter-individual
variation was seen in Midazolam AUC which reﬂ   ects variation in
CYP3A activity.  In our patients the midazolam concentration at 2 hours
correlates with AUC (r2=0.79).  We will correlate in-vivo phenotyping
data for CYP3A4 (using a limited sampling strategy) with levels of
cytotoxic drugs which are metabolised by CYP3A4.
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PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION
OF RH1 DURING A PHASE I CLINICAL TRIAL.
TH Ward 1, S Danson 2, M Dawson 1, H McGrath 3, O Denneny 1,
J Cummings 1, C Dive 1, M Ranson 2
1 Poland, Clinical and Experimental Pharmacology, Paterson Institute
for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road,
Manchester, 2 United Kingdom, Department of Medical Oncology, 
Christie Hospital NHS Trust, Wilmslow Road, Manchester, 3 United 
Kingdom, Cancer Research UK Drug Development Ofﬁ  ce, London
RH1 (2,5-diaziridinyl-3-[hydroxymethyl[-6-methyl-1,4-benzoquinone) is a
novel bioreductively activated drug which is an excellent substrate for DT-
diaphorase (EC. 1.6.99.2). This obligate two-electron reductase diaphorase,
which has been shown to be over expressed in many tumours relative to the
normal tissue, will reduce RH1 to a hydroquinone producing a powerful
DNA cross linking a gent. RH1 is presently undergoing a phase I trial.
Pharmacokinetic analysis of plasma samples taken on day 1 and day 5 of 
cycle 1 showed detectable levels of drug with a half life of approximately 6
min for clearance from the blood. The peak levels range from 17 to 113 nM
with escalating dose. These dose levels are consistent with those causing
signiﬁ  cant  biological activity in vitro. Patient’s  lymphocytes exposed to
RH1 on infusion were analysed using the comet-X assay, which detects
DNA  interstrand cross links. Brieﬂ  y cells were collected and  irradiated 
with gamma radiation as were the control pre-infusion lymphocytes. It was
expected t hat  interstrand cross-links produced  by RH1 would retard t he
migration of DNA during electrophoresis resulting in less DNA in the tail of 
the comets compared to the irradiation only controls. To date 5 patients have
been treated with RH1 and peripheral blood lymphocytes isolated from pre-
infusion and post infusion time points on both day 1 and day 5 of treatment.
These were subjected to the comet-X assay and the amount of DNA present
in the tail of the comets following irradiation was measured. Along with
these samples internal QC samples representing low and medium levels of 
DNA cross linking were run. The pooled data for all patients on day 1 showed 
70-80% DNA in the tail similar in distribution to the irradiated control,
however by day 5 the PBLC population showed peaks at 60-70% DNA in
the tail suggesting low level cross-linking similar to the low level internal
control.  Statistical analysis of comets from all patients on day 5 showed a
signiﬁ  cant difference to those measured on day 1 (p=0.002, T-test).
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THE ROLE OF TUMOUR VASCULAR MATURATION IN  
DETERMINING RESPONSE TO TUBULIN-BINDING VASCULAR 
TARGETING AGENTS
CR Ireson 1, SA Hill 1, G Lewis 1, A Steele 1, C Coralli 1, GU Dachs 1, 
P Barber 1, D Honess 1, C Kanthou 1, D Shima 2, G Tozer 1
1 Gray Cancer Institute, Mount Vernon Hospital, Northwood, 
Middlesex, HA6 2JR, Northwood, United Kingdom, 2 Eyetech
Research Center, 42 Cummings Park, Woburn, MA019801, Woburn, 
United States
Combretastatin A-4-phosphate (CA-4-P), which is isolated from the South
African Bush willow tree Combretum caffrum, shuts down blood ﬂ  ow in
a range of human tumour xenografts in mice. Furthermore, administration
of a single i.v. dose of CA-4-P to patients with advanced solid tumours
caused a signiﬁ  cant decrease in tumour blood ﬂ  ow. Although the speciﬁ  c
tumour characteristics determining susceptibility to CA-4-P have not been
established,  it may  be a consequence of an immature vasculature with
relatively little smooth muscle actin (SMA). Fibrosarcoma cell lines, which
express only single vascular endothelial growth factor (VEGF) isoforms,
were developed from corresponding knock-out mice and grown s.c. in SCID
mice. There was no signiﬁ  cant difference in the growth rate of w/t tumours
and those expressing only VEGF120 or VEGF188 (doubling time~2.5 days).
Tumours were excised, stained for SMA & CD-31 and % of SMA-stained
vessels calculated (=vascular maturity index). VMI was 30, 70 & 100% for
VEGF120, w/t & VEGF188 tumours respectively, conﬁ  rming the importance
of t he  high molecular weight  isoform  in vascular maturation. Tumours
were also grown in dorsal skin ﬂ  ap window chambers in SCID mice for
intravital m icroscopy. Fragments of VEGF120 tumours expanded rapidly
in the chambers despite poor internal vascularization. Within 4 days of
implantation, haemorrhage of the surrounding blood vessels was observed.
In contrast, the rate of VEGF188fragment growth was slower until the tumours
were well vascularized, with narrower vessels and no haemorrhage. It will be
important to determine the vascular response of these tumours to CA-4-P,
in order to understand the functional and morphological characteristics that
impinge on the responsiveness of tumour blood vessels to vascular targeting
agents. 
This work was supported by Cancer Research UK.
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TARGETING NOS EXPRESSION IN HYPOXIC TUMOUR CELLS
TO IMPROVE AQ4N DRUG RESPONSE
EC Chinje, Z Kong, S Singh, RL Cowen, KJ Williams, IJ Stratford 
United Kingdom, University Of Manchester, Manchester
AQ4N is a novel di- AQ4N is a novel di- A N -N-oxide prodrug topoisomerase II inhibitor currently in Phase I  N-oxide prodrug topoisomerase II inhibitor currently in Phase I  N
trial in combination with radiotherapy. We have recently shown that up-regulation of 
inducible-NOS in tumours cells could enhance metabolism of bioreductive prodrugs. 
NOS is highly expressed in a broad spectrum of human cancers and consists of an 
oxidase and a reductase domain. The former is a haem-based protein similar to members
of the P450 family, whereas the reductase domain shares a high degree of sequence
homology with P450 reductase (P450R). Studies to date have revealed a requirement 
for P450 or the presence of both haem and P450R in the reductive metabolism of 
AQ4N. The aim of this study was to evaluate the role of human NOS expression in 
tumours as a potentially exploitable target to improve AQ4N drug response.
We have employed an expression vector containing the cDNA for human iNOS to 
stably transfect human HT1080 (ﬁ  brosarcoma) and MDA231 (breast adenocarcinoma)
tumour cells. Two clones have been selected and used in the study: HT-NOS12 (derived 
from HT1080wt) and MDA-NOS10 (derived from MDA231wt).
Results. AQ4N metabolism and enzyme proﬁ  ling of NOS clones
Cell line Rate of metabolism NOS Activity Reductaseactivity
(nM/min/mg )* (pmol/min/mg) (nmol /min/mg)
AQ4 AQ4M NOSR DTD b5R
HT1080wt n.d (2.28) 6.9 0.89 3.2 244 59.4
HT-iNOS12 10.3 (72.8) 130.5 95.20 24.3 262 54.2
MDA231wt n.d (1.47) 3.9 0.67 3.5 9 34.2
MDA-NOS10 1.5 (94.9) 41.3 66.22 22.1 7 37.4
*Numbers in brackets represent formation rate when AQ4M is used as substrate. n.d.
not detectable.
Results from colony formation assays showed that NOS increased sensitivity to
AQ4N and at low O2 tension (<1%O2). 
In conclusion, our data suggest that the human iNOS enzyme can contribute to the 
reductive metabolism of AQ4N. We show elsewhere (Simendra et al.,this conference) 
that NO production increases the radiosensitivity of hypoxic tumour cells. Hence, the
combination of these two effects provides an opportunity for improving the treatment 
of radiation- and chemo- resistant hypoxic tumours.
P120
SELECTIVE ACTIVATION AND X-LINKING ABILITY OF A
QUINONE-MUSTARD CONJUGATE (MUP03/704) IN VITRO :
AN NQO1-TARGETED PRODRUG FOR CANCER THERAPY
M Volpato 1, PM Loadman 1, N Abou Zied 2, M Jaffar 2,
I Stratford 2, RM Phillips 1
1 United Kingdom, Cancer Research Unit, Bradford University,
Bradford, 2 United Kingdom, School of pharmacy, Manchester 
University, Manchester
NQO1 (NAD(P)H: quinone oxidoreductase 1) is a cytosolic ﬂ  avoprotein that
catalyses the two-electron reductions. It is known to bioreductively activate
certain quinones and elevated levels of NQO1 activity or mRNA have been
observed in human tumours such as NSCLC. NQO1 is therefore a potential
target for rational drug development. The purpose of this study is to evaluate
a novel class of quinone based compounds whereupon a cytotoxic moiety is
released after reduction of the prodrug: the quinone prodrug MUP 03/704
can be bioreductively reduced by NQO1 to give the hydroxyquinone which
spontaneously breaks down to afford a non toxic lactone (MUP 03/702) and
the alkylating agent (MUP 03/706). In the absence of reduction, the prodrug
is potentially non-toxic.
The substrate speciﬁ  city of MUP 03/704 for NQO1 was measured using
spectrophotometry. It exhibited a Km of approximately 940 µM and a Vmax
of 5,77 mmol/min/mg. The ability of MUP 03/704 and MUP 03/706, its
cytotxic moiety, to induce formation of interstrand crosslinks (ICLs) was
evaluated in H460 lung cancer cells (high NQO1 activity) and BE colon
cancer cells (no NQO1 activity), using the comet assay. After 1h exposure,
40 µM of MUP 03/704 concentrations, around 40% of DNA crosslinked
was measured in H460 cells and only 5% in BE cells. In the same settings,
MUP03/706 induced up to 50% in H460 cells and 70% in BE cells. As an
example, high concentrations Mitomycin C can induce up to 90% in H460
cells after 1h exposure, and around but less then 10% at its IC50.
These results suggest that compound MUP 03/704 could be effectively
reduced by NQO1 in cell free system and induced formation of ICLs in
cancer cells expressing the enzyme. Further studies are carried out to further
characterise its pharmacologic features and to investigate the relationship
between its bioactivation and cell lines sensitivity.
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